Insilico Medicine Reinforces Drug Retargeting for Anti Aging
FREMONT, CA: The rapid increase in diseases like cancer, Parkinson’s and multiple sclerosis calls for drugs or treatments that can effectively cure them. To fulfill this motive, Insilico Medicine, a bioinformatics company, uses GPU accelerated NVIDIA computing to discover cures from existing drugs for various disorders.
Insilico reinforces drug retargeting- a process of drug repurposing research to extract benefits of the same drug for various diseases, using Big Data analytics. It will utilize GPU or graphics processing units that work with CPUs to accelerate scientific, analytics and engineering applications. Insilico researchers will generate their own data and find out how existing medications for one ailment can attack another.
Insilico researchers will focus on only those drugs or medications that are already approved and are being used worldwide. This research will target anti aging drugs with the configuration of four NVIDIDA DevBox desktop supercomputers using TESLA K80 GPU accelerators and four Titan X graphics cards.
To compare data from different sources, Insilico has developed various methods to advance proprietary gene expression and proteomic data using Hadoop. Insilico has already created biomarkers for cancer and Alzheimer’s diseases.
“When you’re using deep learning in bioinformatics your only option today is GPU computing. Deep neural networks are evolving and revolutionizing many aspects of our daily lives – in pictures in videos in voice. GPU computing is becoming much more available and more databases, with millions of samples, also are becoming available. So success in deep learning is primarily centered around two factors: being able to utilize the full power of GPU computing, and access to huge databases,” says Dr. Alex Zhavoronkov, CEO, Insilico.